

Supplementary Information for

“Control of Free Volume and Size Exclusion in the Formation of Smectic C Phases for Display Applications”

R. J. Mandle, E. J. Davis, J. P. Sarju, N. Stock, M. S. Cooke, S. A. Lobato, S. J. Cowling and J. W. Goodby


Department of Chemistry, the University of York, Heslington, York, YO10 5DD.

1 Synthesis:

1.2 General Methods.

All chemicals were purchased from Sigma-Aldrich or Apollo Scientific and used as received, without further purification. Solvents were dried by percolation through a column of activated alumina prior to use. NMR spectra were recorded on a JEOL ECX spectrometer operating at 400 MHz (^1H), 100.5 MHz (^{13}C), 376.4 MHz (^{19}F). Silicon NMR spectra were recorded on a JEOL ECS spectrometer operating at 76.4 MHz. One dimensional ^1H NOE NMR experiments were performed on a Bruker Avance 500 spectrometer operating at 500 MHz and 400 MHz (pulse program selnogg [SI1-SI3]) at 298 K in CDCl_3 . Mass spectra were recorded on a Bruker micrOTOF MS-Agilent series 1200LC spectrometer. FTIR spectroscopy was performed using a Shimadzu IR Prestige-21 with Specac Golden Gate diamond ATR IR insert. High-performance liquid chromatography was performed on a Shimadzu Prominence modular HPLC system comprising a LC-20A liquid chromatograph, a DGU-20A₅ degasser, a SIL-20A autosampler, a CBM-20A communication bus, a CTO-20A column oven, and a SPO-20A dual wavelength UV-vis detector. The column used was an Alltech C18 bonded reverse-phase silica column with a 5 μm pore size, an internal diameter of 10 mm and a length of 250 mm. Polarised optical microscopy was performed on a Zeiss Axioskop 40Pol microscope using a Mettler FP82HT hotstage controlled by a Mettler FP90 central processor. Photomicrographs were captured *via* an InfinityX-21 MP digital camera mounted atop the microscope. Differential scanning calorimetry was performed on a Mettler DSC822^e fitted with an autosampler operating with Mettler Star^e software and calibrated before use against an indium standard (onset = 156.55 ± 0.2 °C, $\Delta H = 28.45 \pm 0.40$ Jg⁻¹) under an atmosphere of dry nitrogen. Small angle X-ray diffraction was performed using a Bruker D8 Discover equipped with a temperature controlled, bored graphite rod furnace, custom built at the University of York. Samples were filled into 1mm capillary tubes and aligned magnetically with a 1T magnet. Diffraction patterns were collected as a function of temperature and the data processed using Bruker DIFFRAC.SUITE EVA software. Computational studies were performed using Gaussian 09. [SI4]

Experimental



4-Pentyloxybenzoic acid (13)


1-Bromopentane (25 g, 20.5 ml, 165.5 mmol) was added dropwise to a stirred, heated suspension of potassium carbonate (45 g, 330 mmol) and methyl 4-hydroxybenzoate (22.8 g, 150 mmol) in acetone (200 ml) under reflux. The solution was stirred for 16h, filtered and the solvent removed *in vacuo*. The crude residue was dissolved into diethyl ether (300 ml), which was washed with sodium hydroxide solution (2M, 200 ml). The organic layer was dried over MgSO₄ and dried *in vacuo* to yield crude methyl 4-pentyloxybenzoate. The crude methyl 4-pentyloxybenzoate was dissolved into ethanol (120 ml), solid KOH (50 g) and water (10 ml) were added and the resulting solution was heated under reflux for 1 h, then cooled to r.t. and diluted with water (250 ml) and filtered. The filtrate was acidified to pH 1 with 36% HCl, causing the title compound to precipitate as a white solid. The solid was collected by filtration and dried under reduced pressure affording the title compound as a powdery white solid.

Yield: 25.4 g (81%)

MP: 127 °C

¹H NMR (400 MHz, DMSO-D₆): 0.82 (3H, t, *J* = 7.0, CH₃-CH₂), 1.22 – 1.37 (4H, m, CH₃-(CH₂)₂-CH₂), 1.65 (2H, Quintet, *J* = 7.0, CH₂-CH₂-CH₂OAr), 3.95 (2H, t, *J* = 7.0, CH₂-CH₂OAr), 6.90 (2H, ddd, *J* = 2.1, *J* = 2.8, *J* = 8.9, Ar), 7.80 (2H, ddd, *J* = 2.1, *J* = 2.8, *J* = 8.9, Ar)

MS *m/z* (ESI⁺): 231.0988 (100%, C₁₂H₁₆NaO₃, M+Na), 209.1170 (C₁₂H₁₇O₃, M+H)



4-(2,4,4-Trimethylpentyl)oxybenzoic acid (14)

To a stirred solution of 2,4,4-trimethylpentan-1-ol (5 g, 38.46 mmol), triphenyl phosphine (10.1 g, 38.46 mmol) and methyl 4-hydroxybenzoate (5.9 g, 38.46 mmol) in anhydrous THF (50 ml), under an atmosphere of dry nitrogen, was added neat DIAD (7.8 g, 7.5 ml, 38.46 mmol) dropwise over a period of 0.5h. The resulting solution was stirred for 16h, and the solvent removed *in vacuo*. Ethanol (100 ml) was added to the crude residue and the solution was heated under reflux before the addition of 4M sodium hydroxide solution (50 ml). The solution was heated under reflux for 16 h, cooled to r.t. and diluted with water (100 ml) and filtered. The filtrate was acidified to pH 1 with 36% HCl, the resulting precipitate collected by filtration and recrystallised from ethanol giving the title compound as translucent needles.


Yield: 9.0 g (88.6%)

MP: 106.3 °C

¹H NMR (400 MHz, Acetone-D₆): 0.79 (9H, s, C-(CH₃)₃), 0.88 (3H, d, *J* = 6.4, CH₃-CH), 1.13 (1H, dd, *J* = 6.1, *J* = 14.0, (CH₃)₃C-CH₂-CH(CH₃)-CH₂), 1.47 (1H, dd, *J* = 3.7, *J* = 14.0, (CH₃)₃C-CH₂-CH(CH₃)-CH₂), 1.97 – 2.07 (1H, m, (CH₃)₃C-CH₂-CH(CH₃)-CH₂), 3.81 (1H, dd, *J* = 7.0, *J* = 9.2, CH₃CH-CH₂-OAr), 3.90 (1H, dd, *J* = 6.1, *J* = 9.2, CH₃CH-CH₂-OAr), 6.90 (2H, ddd, *J* = 2.1, *J* = 2.8, *J* = 8.9, Ar), 7.80 (2H, ddd, *J* = 2.1, *J* = 2.8, *J* = 8.9, Ar).

MS M/Z (ESI⁺): 273.1462 (100%, C₁₅H₂₂NaO₃, M+Na), 251.1650 (C₁₅H₂₃O₃, M+H)

IR: 547, 640, 771, 840, 941, 1026, 1118, 1157, 1249, 1296, 1427, 1604, 1674, 2553, 2669, 2826, 2947



4-(3-(Trimethylsilyl)propoxy)benzoic acid (15)

Quantities used: Methyl 4-hydroxybenzoate (5.5 g, 36.36 mmol), triphenylphosphine (7.9 g, 30.303 mmol), DIAD (6.1 g, 5.9 ml, 30.303 mmol), 3-(trimethylsilyl)propan-1-ol (4 g, 30.303 mmol), anhydrous THF (20 ml), then aqueous 4M sodium hydroxide (50 ml), ethanol (50 ml). The experimental procedure was as described in the synthesis of compound **13**, giving the title compound as a white powder.

Yield: 7.1 g (93 %)

MP: 172 °C


^1H NMR (400 MHz, DMSO- D_6): 0.00 (3H, s, Si-(CH_3) $_3$), 0.58 (2H, m, (CH_3) $_3$ -Si- CH_2), 1.66 – 1.76 (2H, m, (CH_3) $_3$ Si- CH_2 - CH_2 - CH_2 O), 3.98 (2H, t, $J = 6.7$, CH_2OAr), 6.98 (2H, ddd, $J = 2.1$, $J = 2.8$, $J = 8.9$, Ar), 7.86 (2H, ddd, $J = 2.1$, $J = 2.8$, $J = 8.9$, Ar), 12.60 (1H, BrS, ArCOOH)

^{13}C NMR (100.5 MHz, Acetone- D_6): -2.49, 12.21, 23.60, 70.64, 114.16, 122.60, 131.69, 163.11, 166.61

^{29}Si NMR (79.42 MHz, Acetone- D_6): 0.01 (s, (CH_3) $_3$ Si- CH_2)

MS M/Z (ESI+): 275.1086 (100%, $\text{C}_{13}\text{H}_{20}\text{SiNaO}_3$, M+Na), 253.1258 ($\text{C}_{13}\text{H}_{21}\text{SiO}_3$, M+H)

IR: 547, 640, 694, 771, 833, 894, 956, 995, 1165, 1242, 1288, 1427, 1604, 1666, 2538, 2654, 2800, 2870, 2939



1-Bromo-2,3-difluoro-4-((2,4,4-trimethylpentyl)oxy)benzene (4)

4-Bromo-2,3-difluorophenol (8 g, 38.462 mmol), triphenylphosphine (10 g, 38.462 mmol) and 2,4,4-trimethylpentanol (5 g, 36.462 mmol) were dissolved into anhydrous THF (100 ml) before the dropwise addition of DIAD (7.8 g, 7.6 ml, 38.462 mmol). The reaction was followed *via* TLC and upon complete consumption of the starting materials (1 h) the solvents were removed *in vacuo*. The title compound was isolated as a straw coloured oil *via* flash chromatography with DCM as the eluent ($R_f = 0.95$).

Yield: 11.4 g (93%)


^1H NMR (400 MHz, CDCl_3): 0.91 (9H, s, C-(CH_3)₃), 1.05 (3H, d, $J = 6.4$, CH_3 -CH), 1.13 (1H, dd, $J = 6.1$, $J = 14.0$, (CH_3)₃C- CH_2 -CH(CH₃)-CH₂), 1.36 (1H, dd, $J = 4.0$, $J = 14.0$, (CH_3)₃C- CH_2 -CH(CH₃)-CH₂), 1.96 – 2.05 (1H, m, (CH_3)₃C-CH₂-CH(CH₃)-CH₂), 3.67 (1H, dd, $J = 7.3$, $J = 8.5$, CH_3 CH- CH_2 -OAr), 3.80 (1H, dd, $J = 6.4$, $J = 8.5$, CH_3 CH- CH_2 -OAr), 6.61 (2H, ddd, $J = 2.1$, $J = 7.6$, $J = 9.2$, Ar), 7.14 (2H, ddd, $J = 2.1$, $J = 7.6$, $J = 9.2$, Ar)

^{13}C NMR (100.5 MHz, CDCl_3): 19.86, 29.67, 29.87, 31.01, 47.24, 76.02, 110.31 (d, $J = 3.1$), 126.30 (d, $J = 4.6$), 130.43 (d, $J = 12.3$, $J = 362.87$), 142.16 (dd, $J = 14.6$, $J = 251.6$), 148.42 (dd, $J = 3.1$, $J = 8.4$), 148.83 (dd, $J = 14.6$, $J = 247.0$)

^{19}F NMR (376.4 MHz, CDCl_3): -152.72 (ddd, $J = 2.3$, $J = 8.0$, $J = 20.7$, Ar-F), -129.21 (ddd, $J = 2.3$, $J = 8.0$, $J = 20.7$, Ar-F)

MS M/Z (ESI+): 321.0672 (100%, $\text{C}_{14}\text{H}_{19}\text{F}_2\text{OBr}$, M + H)

IR: 594, 732, 786, 879, 972, 1080, 1219, 1303, 1365, 1465, 1612, 2870, 2954



(3-(4-Bromo-2,3-difluorophenoxy)propyl)trimethylsilane (5)

Quantities used: 4-Bromo-2,3-difluorophenol (2.4 g, 11.364 mmol), triphenylphosphine (2.9 g, 11.364 mmol), DIAD (2.3 g, 2.3 ml, 11.364 mmol), trimethylsilyl)propan-1-ol (1.5 g, 11.364 mmol), THF (60 ml). The experimental procedure was as described in the synthesis of compound **4**. The title compound was isolated as a straw coloured oil *via* flash chromatography with DCM as the eluent ($R_f = 0.95$).

Yield: 2.9 g (79 %)


^1H NMR (400 MHz, CDCl_3): 0.00 (9H, s, $(\text{CH}_3)_3\text{Si}$), 0.53 – 0.60 (2H, m, $\text{CH}_2\text{-CH}_2\text{-Si}(\text{CH}_3)_3$), 1.71 – 1.84 (2H, m, $\text{OCH}_2\text{-CH}_2\text{-CH}_2$), 3.94 (2H, t, $J = 7.0$, CH_2O), 6.56 – 6.66 (1H, m, Ar), 7.16 (1H, m, Ar)

^{13}C NMR (100.5 MHz, CDCl_3): -1.82, 12.30, 23.67, 72.54, 100.34 (d, $J = 18.4$), 110.24, 126.26 (d, $J = 4.6$), 142.00 (dd, $J = 16.0$, $J = 250.1$), 148.12 (dd, $J = 2.3$, $J = 8.2$), 148.70 (dd, $J = 12.3$, $J = 247.0$),

^{19}F NMR (376.4 MHz, CDCl_3): -154.77 (1F, dd, $J = 6.9$, $J = 19.5$, Ar-F), -129.1 (1F, d, $J = 19.5$, Ar-F)

^{29}Si NMR (79.4 MHz, CDCl_3): 2.47 (s, $(\text{CH}_3)_3\text{Si-CH}_2$)

MS M/Z (ESI+): 325.0266 (100%, $\text{C}_{12}\text{H}_{17}\text{F}_2\text{OBrSi}$, M + H)



2',3'-Difluoro-4'-(pentyloxy)-[1,1'-biphenyl]-4-ol (8)

A suspension of (2',3'-difluoro-4'-(pentyloxy)-[1,1'-biphenyl]-4-yl)boronic acid (4 g, 12.5 mmol) in diethyl ether (100 ml) was heated under reflux with stirring for 30 minutes, before the addition of 30% hydrogen peroxide (50 ml) in one portion. The suspension rapidly dissolved, giving a golden yellow coloured solution, and the reaction was monitored by TLC until no further consumption of the boronic acid was noted (30 minutes). The biphasic reaction mixture was cooled to ambient temperature before separating and discarding the aqueous layer. The ethereal solution was washed with water (3 x 100 ml), dried over $MgSO_4$ and the solvent removed *in vacuo* to give a yellow solid. This was subjected to flash chromatography with DCM as the eluent affording the product ($R_f = 0.35$) as a white solid.

Yield: 3.4 g (93 %)

MP: 119.5 °C


1H NMR (400 MHz, $CDCl_3$): 0.91 (3H, t, $J = 7.0$, $\underline{CH_3-CH_2}$), 1.31 – 1.51 (4H, m, $CH_3-(\underline{CH_2})_2-CH_2$), 1.81 (2H, Quintet, $J = 7.0$, $OCH_2-\underline{CH_2}-CH_2$), 4.04 (2H, t, $J = 7.0$, CH_2O), 4.91 (1H, s, Ar-OH), 6.74 (1H, ddd, $J = 1.8$, $J = 7.7$, $J = 8.8$, Ar-H), 6.87 (2H, ddd, $J = 2.2$, $J = 2.9$, $J = 8.8$, Ar), 7.01 (1H, td, $J = 2.2$, $J = 8.8$, Ar), 7.31 (2H, dddd, $J = 1.5$, $J = 2.9$, $J = 3.7$, $J = 8.8$, Ar)

^{13}C NMR (100.5 MHz, $CDCl_3$): 13.97, 22.38, 27.99, 28.83, 69.89, 109.53 (d, $J = 2.3$), 115.43, 122.59 (d, $J = 10.7$), 123.22 (t, $J = 4.6$), 127.55, 130.06 (d, $J = 3.1$), 141.72 (dd, $J = 15.3$, $J = 247.0$), 147.38 (dd, $J = 3.1$, $J = 8.4$), 148.76 (dd, $J = 10.7$, $J = 247.8$), 155.06

^{19}F NMR (376.4 MHz, $CDCl_3$): -158.76 (1F, ddd, $J = 2.3$, $J = 6.9$, $J = 19.5$, Ar-F), -142.01 (1F, dd, $J = 6.9$, $J = 19.5$, Ar-F)

MS M/Z (ESI+): 315.1157 (100%, $C_{17}H_{18}F_2NaO_2$, M+Na)

IR: 501, 617, 732, 810, 894, 972, 1072, 1195, 1249, 1288, 1365, 1612, 2862, 2931, 3433



2',3'-Difluoro-4'-((2,4,4-trimethylpentyl)oxy)-[1,1'-biphenyl]-4-ol (9)

To a stirred, thoroughly degassed suspension of compound **4** (5 g, 15.625 mmol) in THF (100 ml) and aqueous 2M sodium carbonate (100 ml) heated under reflux was added Pd(PPh₃)₄ (100 mg) in one portion. The resulting solution was stirred for 30 minutes before the addition of 4-hydroxybenzeneboronic acid (2.4 g, 17.188 mmol) in one portion. The reaction solution was then stirred for a further 14h. The biphasic solution was cooled to ambient temperature and diethyl ether added. The aqueous layer was separated from the organic, acidified with 6M HCl and washed with diethyl ether (3 x 50 ml) before discarding. The combined ethereal extracts were dried over Na₂SO₄, and concentrated *in vacuo* to a dark brown oil. The target compound was obtained *via* flash chromatography over silica gel with DCM as the eluent (*R_f* = 0.35), affording a viscous straw coloured oil. The crude oil was triturated with hot petroleum ether and allowed to cool to ambient temperature, at which point the title compound precipitated out as a white solid and was collected by filtration.

Yield: 4.2 g (80%)

MP: 63.2 °C


¹H NMR (400 MHz, CDCl₃): 0.94 (9H, s, C-(CH₃)₃), 1.09 (3H, d, *J* = 6.1, CH₃-CH), 1.10 – 1.15 (1H, m, (CH₃)₃C-CHH-CH(CH₃)-CH₂) 1.36 – 1.42 (1H, m, (CH₃)₃C-CHH-CH(CH₃)-CH₂), 1.99 – 2.10 (1H, M, (CH₃)₃C-CH₂-CH(CH₃)-CH₂), 3.73 (1H, td, *J* = 7.3, *J* = 8.9, CH₃CH-CHH-OAr), 3.87 (1H, dd, *J* = 5.8, *J* = 8.9, CH₃CH-CHH-OAr), 6.75 (1H, m, dd, *J* = 2.1, *J* = 8.5, Ar), 6.89 (2H, ddd, *J* = 2.1, *J* = 3.1, *J* = 8.9, Ar), 7.03 (1H, td, *J* = 2.1, *J* = 8.5, Ar), 7.38 (2H, dddd, *J* = 1.5, *J* = 2.8, *J* = 3.7, *J* = 8.5, Ar)

¹³C NMR (100.5 MHz, CDCl₃): 19.97, 29.73, 29.93, 31.07, 47.31, 75.98, 109.63 (d, *J* = 3.1), 115.56, 122.66 (d, *J* = 10.7), 123.32 (t, *J* = 3.8), 127.63, 130.17 (d, *J* = 2.3), 141.98 (dd, *J* = 14.6, *J* = 247.0), 147.46 (dd, *J* = 3.1, *J* = 9.2), 148.93 (dd, *J* = 14.6, *J* = 247.0), 155.26

¹⁹F NMR (376.4 MHz, CDCl₃): -158.73 (1F, ddd, *J* = 2.3, *J* = 8.0, *J* = 19.5, Ar-F), -142.07 (1F, dd, *J* = 8.0, *J* = 19.5, Ar-F)

MS M/Z (ESI+): 335.1809 (100%, C₂₀H₂₅F₂O₂, M + H)

IR: 509, 617, 648, 740, 794, 894, 972, 1072, 1195, 1249, 1365, 1465, 1612, 2870, 2954, 3232, 3402



2',3'-Difluoro-4'-(3-(trimethylsilyl)propoxy)-[1,1'-biphenyl]-4-ol (10)

Quantities used: Compound **5** (2 g, 6.1919 mmol), 4-hydroxybenzeneboronic acid (1.272 g, 9.2879 mmol), Pd(PPh₃)₄ (50 mg), THF (40 ml), 2M aqueous sodium carbonate (40 ml). The experimental procedure was as described in the preparation of compound **9**. The title compound was purified by flash chromatography with DCM as the eluent (*R_f* = 0.35) and recrystallised from petroleum ether (40-60), giving the title compound a white solid.

Yield: 1.7 g (82%)

MP: 88.5 °C

¹H NMR (400 MHz, CDCl₃): 0.00 (9H, s, CH₃Si-CH₂), 0.54 – 0.61 (2H, m, CH₃Si-CH₂-CH₂), 1.75 – 1.86 (2H, m, CH₂-CH₂-CH₂OAr), 3.99 (2H, t, *J* = 7.0, CH₂OAr), 6.73 (1H, td, *J* = 2.1, *J* = 8.9, Ar), 6.87 (2H, ddd, *J* = 2.1, *J* = 2.8, *J* = 8.9, Ar), 7.01 (1H, ddd, *J* = 2.1, *J* = 8.2, *J* = 8.9, Ar), 7.36 (2H, dddd, *J* = 1.5, *J* = 3.1, *J* = 3.4, *J* = 8.5, Ar)


¹³C NMR (100.5 MHz, CDCl₃): -1.77, 1.00, 12.36, 23.77, 72.48, 109.69 (d, *J* = 3.1), 115.56, 122.73 (d, *J* = 11.5), 123.39 (t, *J* = 3.8), 127.61, 130.16 (d, *J* = 3.1), 141.98 (dd, *J* = 14.6, *J* = 246.3), 147.46 (dd, *J* = 3.1, *J* = 8.4), 148.89 (dd, *J* = 10.7, *J* = 247.8), 155.29

¹⁹F NMR (376.4 MHz, CDCl₃): -158.79 (1F, dd, *J* = 6.9, *J* = 25.29, Ar-F), -142.00 (1F, dd, *J* = 6.9, *J* = 25.29, Ar-F)

²⁹Si NMR (79.4 MHz, CDCl₃): 2.50 (s, (CH₃)₃-Si-CH₂)

MS M/Z (ESI⁺): 359.1264 (C₁₈H₂₂F₂NaO₂Si, M + Na), 337.1441 (100%, C₁₈H₂₃F₂O₂Si, M + H)

IR: 524, 617, 694, 748, 833, 1072, 1180, 1242, 1288, 1388, 1442, 1504, 1612, 2885, 2954, 3248



2',3'-Difluoro-4'-(pentyloxy)-[1,1'-biphenyl]-4-yl 4-(pentyloxy)benzoate (16)

Compound **8** (300 mg, 1.0274 mmol), compound **12** (228 mg, 1.0274 mmol), EDAC (294 mg, 1.5411 mmol), DMAP (catalytic) were dissolved into DCM (10 ml), and the resulting solution stirred for 18 h. The solvent was removed *in vacuo* and the crude residues purified by flash chromatography with DCM as the eluent ($R_f = 0.9$) followed by recrystallisation from ethanol, giving the title compound as fine white needles.

Yield: 376 mg (74%)

^1H NMR (400 MHz, CDCl_3): 0.87 (6H, t, $J = 7.32$, 2 x $\text{CH}_3\text{-CH}_2$), 1.27 – 1.47 (8H, m, 2 x $\text{CH}_3\text{-(CH}_2)_2\text{-CH}_2$), 1.76 (4H, m, 2 x $\text{CH}_2\text{-CH}_2\text{-CH}_2\text{O}$), 3.97 (2H, t, $J = 7.32$, $\text{CH}_2\text{-CH}_2\text{-OC}_6\text{H}_4$), 4.00 (3H, t, $J = 7.32$, $\text{CH}_2\text{-CH}_2\text{-OC}_6\text{H}_2\text{F}_2$), 6.72 (1H, ddd, $J = 2.1$, $J = 7.3$, $J = 8.9$, Ar-H), 6.90 (2H, ddd, $J = 1.8$, $J = 2.8$, $J = 8.9$, Ar), 7.02 (1H, td, $J = 2.1$, $J = 8.9$, Ar), 7.19 (2H, ddd, $J = 1.8$, $J = 2.8$, $J = 8.5$, Ar), 7.47 (2H, dddd, $J = 1.2$, $J = 3.1$, $J = 3.4$, $J = 8.5$, Ar), 8.08 (2H, ddd, $J = 1.8$, $J = 2.8$, $J = 8.9$, Ar)


^{13}C NMR (100.5 MHz, CDCl_3): 13.99, 22.40, 22.42, 28.01, 29.11, 28.77, 28.83, 68.30, 69.84, 109.52 (d, $J = 3.1$), 114.29, 121.38, 121.92, 122.15 (d, $J = 11.5$), 123.55 (t, $J = 4.6$), 129.78 (d, $J = 3.1$), 132.30, 132.42, 141.84 (dd, $J = 15.3$, $J = 247.8$), 147.89 (dd, $J = 3.1$, $J = 8.4$), 148.86 (dd, $J = 11.5$, $J = 247.8$), 150.56, 163.58, 164.91

^{19}F NMR (376.4 MHz, CDCl_3): -158.62 (dd, $J = 6.9$, $J = 19.5$, Ar-F), -141.66 (dd, $J = 6.9$, $J = 19.5$, Ar-F)

MS M/Z (ESI+): 505.2148 (100%, $\text{C}_{29}\text{H}_{32}\text{F}_2\text{NaO}_4$, M+Na), 483.2345 ($\text{C}_{29}\text{H}_{33}\text{F}_2\text{O}_4$, M+H)

IR: 756, 794, 887, 1018, 1072, 1165, 1211, 1465, 1604, 1720, 1913, 2330 2870, 2954

Assay (HPLC, C18, 235/260 nm, 100% H_3CCN): 99.62%



2',3'-Difluoro-4'-(pentyloxy)-[1,1'-biphenyl]-4-yl 4-((2,4,4-trimethylpentyl)oxy)benzoate (17)

Quantities used: Compound **8** (300 mg, 1.027 mmol) compound **14** (271 mg, 1.084 mmol), EDAC (294 mg, 1.541 mmol), DMAP (catalytic), DCM (2ml). The experimental procedure was as described in the preparation of compound **16**. The title compound was purified by flash chromatography with DCM as the eluent ($R_f = 0.9$) and recrystallised from ethanol/acetone (15:1), giving the title compound as white plates.

Yield: 411 mg (76%)

^1H NMR (400 MHz, CDCl_3): 0.83 – 0.90 (12H, m, $\text{CH}_3\text{-(CH}_2\text{)}_4\text{OAr}$ + $(\text{CH}_3\text{)}_3\text{-C}$), 0.98 – 1.09 (3H, d, $J = 6.7$, $\text{CH}_3\text{-CH}$), 1.05 (1H, dd, $J = 6.1$, $J = 14.0$, $(\text{CH}_3\text{)}_3\text{C-CHH-CH(CH}_3\text{)-}$), 1.27 – 1.45 (5H, m $\text{CH}_3\text{-(CH}_2\text{)}_2\text{-CH}_2$ + $\text{CHH-C(CH}_3\text{)}_3$), 1.76 (2H, Quintet, $J = 7.0$, $\text{OCH}_2\text{-CH}_2\text{-CH}_2$), 1.89 – 2.01 (1H, m, $(\text{CH}_3\text{)-CH-CH}_2\text{OAr}$), 3.66 (1H, dd, $J = 7.32$, $J = 8.9$, $(\text{CH}_3\text{)CH-CHHOAr}$), 3.79 (1H, dd, $J = 5.8$, $J = 8.9$, $(\text{CH}_3\text{)CH-CHHOAr}$), 3.98 (2H, t, $J = 6.7$, CH_2O), 6.75 (1H, ddd, $J = 1.8$, $J = 8.2$, $J = 8.9$, Ar-H), 6.89 (2H, ddd, $J = 2.1$, $J = 2.8$, $J = 9.2$, Ar), 7.01 (1H, td, $J = 2.4$, $J = 8.5$, Ar), 7.18 (2H, ddd, $J = 1.8$, $J = 2.8$, $J = 8.9$, Ar), 7.46 (2H, dddd, $J = 1.5$, $J = 3.4$, $J = 5.5$, $J = 8.5$, Ar), 8.07 (2H, ddd, $J = 1.8$, $J = 2.8$, $J = 8.9$, Ar)


^{13}C NMR (100.5 MHz, CDCl_3): 13.97, 19.90, 22.38, 27.99, 28.82, 29.50, 29.84, 30.95, 47.27, 69.81, 73.38, 109.48 (d, $J = 2.3$), 114.31, 121.33, 121.91, 122.12 (d, $J = 10.7$), 123.55 (t, $J = 3.8$), 129.76 (d, $J = 2.3$), 132.28, 132.39, 141.81 (dd, $J = 14.6$, $J = 247.0$), 147.88 (dd, $J = 3.1$, $J = 8.4$), 148.85 (dd, $J = 10.7$, $J = 248.6$), 150.55, 163.67, 164.89

^{19}F NMR (376.4 MHz, CDCl_3): -158.61 (1F, ddd, $J = 2.3$, $J = 5.8$, $J = 19.5$, Ar-F), -146.65 (1F, dd, $J = 5.8$, $J = 19.5$, Ar-F)

MS M/Z (ESI+): 547.2622 (100%, $\text{C}_{32}\text{H}_{38}\text{F}_2\text{NaO}_4$, M+Na), 525.2836 ($\text{C}_{32}\text{H}_{39}\text{F}_2\text{O}_4$, M+H)

IR: 624, 763, 794, 1018, 1064, 1165, 1249, 1465, 1597, 1720, 1913, 2870, 2954

Assay (HPLC, C18, 235/260 nm, 100% H_3CCN): 98.8%



2',3'-Difluoro-4'-(pentyloxy)-[1,1'-biphenyl]-4-yl 4-(3-(trimethylsilyl)propoxy)benzoate (18)

Quantities used: Compound **8** (300 mg, 1.027 mmol), compound **15** (258 mg, 1.027 mmol), EDAC (294 mg, 1.541 mmol), DMAP (catalytic), DCM (5 ml). The experimental procedure was as described in the preparation of compound **16**. The title compound was purified by flash chromatography with DCM as the eluent ($R_f = 0.9$) and recrystallised from ethanol/acetone (20:1), giving the title compound as white plates.

Yield: 470 mg (87%)

$^1\text{H NMR}$ (400 MHz, CDCl_3): 0.00 (9H, s, $(\text{CH}_3)_3\text{Si}$), 0.59 (2H, m, $\text{CH}_2\text{-CH}_2\text{-Si}(\text{CH}_3)_3$), 0.90 (3H, t, $J = 7.0$, $\text{CH}_3\text{-CH}_2$), 1.31 – 1.48 (4H, m, $\text{CH}_3\text{-(CH}_2)_2\text{-CH}_2$), 1.81 (2H, Quintet, $J = 7.0$, $\text{OCH}_2\text{-CH}_2\text{-CH}_2$), 3.99 (2H, t, $J = 7.0$, $\text{OCH}_2\text{-CH}_2\text{-CH}_2\text{-Si}(\text{CH}_3)_3$), 4.04 (2H, t, $J = 7.0$, CH_2O), 6.75 (1H, ddd, $J = 1.8$, $J = 7.7$, $J = 8.8$, Ar-H), 6.83 (2H, ddd, $J = 2.2$, $J = 2.9$, $J = 8.8$, Ar), 7.05 (1H, td, $J = 2.2$, $J = 8.8$, Ar), 7.23 (2H, ddd, $J = 2.1$, $J = 2.8$, $J = 8.9$, Ar), 7.31 (2H, dddd, $J = 1.5$, $J = 2.9$, $J = 3.7$, $J = 8.8$, Ar), 8.11 (2H, ddd, $J = 2.1$, $J = 2.8$, $J = 8.9$, Ar)

$^{13}\text{C NMR}$ (100.5 MHz, CDCl_3): -1.78, 12.51, 13.97, 22.38, 23.68, 27.99, 28.82, 69.81, 70.90, 109.47 (d, $J = 3.1$), 114.26, 121.36, 121.91, 122.12 (d, $J = 10.7$), 123.54 (t, $J = 4.6$), 129.76 (d, $J = 3.1$), 123.29, 123.39, 141.81 (dd, $J = 15.3$, $J = 247.0$), 147.90 (dd, $J = 2.3$, $J = 7.7$), 148.84 (dd, $J = 10.7$, $J = 249.3$), 150.54, 163.52, 164.88


$^{19}\text{F NMR}$ (376.4 MHz, CDCl_3): -158.62 (1F, ddd, $J = 2.3$, $J = 8.0$, $J = 19.5$, Ar-F), -141.66 (1F, dd, $J = 8.0$, $J = 19.5$, Ar-E)

$^{29}\text{Si NMR}$ (79.4 MHz, CDCl_3): 2.47 (s, $(\text{CH}_3)_3\text{Si-CH}_2$)

MS M/Z (ESI+): 549.2158 (100%, $\text{C}_{30}\text{H}_{36}\text{F}_2\text{O}_4\text{Si}$, M+Na), 527.2398 ($\text{C}_{30}\text{H}_{37}$, $\text{F}_2\text{O}_4\text{Si}$, M+H)

IR: 493, 532, 617, 694, 756, 840, 1002, 1064, 1165, 1249, 1396, 1465, 1597, 1728, 2870, 2954

Assay (HPLC, C18, 235/260 nm, 100% H_3CCN): 99.0%



2',3'-Difluoro-4'-((2,4,4-trimethylpentyl)oxy)-[1,1'-biphenyl]-4-yl 4-(pentyloxy)benzoate (19)

Quantities used: Compound **9** (200 mg, 0.5988 mmol), compound **13** (146.2 mg, 0.6586 mmol), EDAC (171.6 mg, 0.898 mmol), DMAP (catalytic), DCM (5 ml). The experimental procedure was as described in the preparation of compound **16**. The title compound was purified by flash chromatography with DCM as the eluent ($R_f = 0.95$) and recrystallised from ethanol, giving the title compound as fine white needles.

Yield: 220 mg (68%)

^1H NMR (400 MHz, CDCl_3): 0.84 – 0.91 (12H, m, $(\text{CH}_3)_3\text{C} + \text{CH}_2\text{-CH}_3$), 1.04 (3H, d $J = 6.7$, $\text{CH}_3\text{-CH}$), 1.07 (1H, dd, $J = 6.1$, $J = 14.3$, $(\text{CH}_3)_3\text{C-CHH-CHCH}_3$), 1.28 – 1.51 (5H, m, $\text{CH}_3\text{-(CH}_2)_2\text{-CH}_2 + (\text{CH}_3)_3\text{C-CHH-CHCH}_3$), 1.76 (2H, Quintet, $J = 6.7$, $\text{CH}_3\text{-(CH}_2)_2\text{-CH}_2\text{-CH}_2\text{OAr}$), 1.93 – 2.05 (1H, m, $(\text{CH}_3)_3\text{C-CH}_2\text{-CHCH}_3$), 3.68 (1H, dd, $J = 7.6$, $J = 8.9$, $\text{CH}_3\text{CH-CHHOAr}$), 3.82 (1H, dd, $J = 5.8$, $J = 8.9$, $\text{CH}_3\text{CH-CHHOAr}$), 3.97 (2H, t, $J = 6.7$, CH_2OAr), 6.71 (1H, m, 6.91 (2H, ddd, $J = 1.8$, $J = 2.8$, $J = 8.9$, Ar), 7.02 (1H, td, $J = 2.1$, $J = 8.5$, Ar), 7.46 (2H, m, Ar), 8.08 (2H, ddd, $J = 1.8$, $J = 2.8$, $J = 8.9$, Ar)


^{13}C NMR (100.5 MHz, CDCl_3): 14.00, 19.87, 22.42, 28.11, 28.77, 29.62, 29.82, 30.98, 47.20, 68.30, 75.80, 109.47 (d, $J = 2.3$), 114.28, 121.38, 121.92, 121.10 (d, $J = 10.7$), 123.53 (t, $J = 3.8$), 129.78 (d, $J = 3.1$), 132.23, 132.43, 141.81 (dd, $J = 14.6$, $J = 247.0$), 148.06 (dd, $J = 2.3$, $J = 7.7$), 148.81 (dd, $J = 10.7$, $J = 248.6$), 150.54, 163.67, 164.92

^{19}F NMR (376.4 MHz, CDCl_3): -158.56 (1F, ddd, $J = 2.3$, $J = 8.0$, $J = 19.5$, Ar-F), -141.71 (1F, dd, $J = 8.0$, $J = 19.5$, Ar-F)

MS M/Z (ESI+): 547.2625 ($\text{C}_{32}\text{H}_{38}\text{F}_2\text{NaO}_4$, M + Na), 525.2786 (100%, $\text{C}_{32}\text{H}_{39}\text{F}_2\text{O}_4$, M + H)

IR: 524, 617, 756, 794, 887, 1018, 1064, 1172, 1203, 1249, 1311, 1404, 1465, 1604, 1728, 2870, 2939

Assay (HPLC, C18, 235/260 nm, 100% H_3CCN): 99.4%



2',3'-Difluoro-4'-(3-(trimethylsilyl)propoxy)-1,1'-biphenyl]-4-yl 4-(pentyloxy)benzoate (20)

Quantities used: Compound **10** (150 mg, 0.4464 mmol), compound **13** (208 mg, 1 mmol), EDAC (191 mg, 1 mmol), DMAP (cat), DCM (5 ml). The experimental procedure was as described in the preparation of compound **16**. The title compound was purified by flash chromatography with DCM as the eluent ($R_f = 0.95$) and recrystallised from ethanol, giving the title compound as colourless plates.

Yield: 230 mg (95%)

^1H NMR (400 MHz, CDCl_3): 0.00 (9H, s, $(\text{CH}_3)_3\text{Si}$), 0.59 (2H, m, $\text{CH}_2\text{-CH}_2\text{-Si}(\text{CH}_3)_3$), 0.91 (3H, t, $J = 7.0$, $\text{CH}_3\text{-CH}_2$), 1.30 – 1.48 (4H, m, $\text{CH}_3\text{-(CH}_2)_2\text{-CH}_2 + (\text{CH}_3)_3\text{Si-CH}_2\text{-CH}_2\text{-CH}_2\text{O}$), 1.74 – 1.86 (2H, m, $\text{OCH}_2\text{-CH}_2\text{-CH}_2$), 3.97 – 4.04 (4H, m, $\text{OCH}_2\text{-C}_4\text{H}_9 + \text{OCH}_2\text{-CH}_2\text{-CH}_2\text{-Si}(\text{CH}_3)_3$), 6.75 (1H, ddd, $J = 1.8$, $J = 7.7$, $J = 9.2$, Ar-H), 6.93 (2H, ddd, $J = 1.8$, $J = 2.9$, $J = 8.8$, Ar), 7.05 (1H, td, $J = 1.8$, $J = 8.8$, Ar), 7.23 (2H, ddd, $J = 1.8$, $J = 2.8$, $J = 8.8$, Ar), 7.48 – 7.54 (2H, m, Ar), 8.11 (2H, ddd, $J = 2.2$, $J = 2.6$, $J = 9.2$, Ar)

^{13}C NMR (100.5 MHz, CDCl_3): -1.66, 12.47, 14.09, 22.53, 23.88, 28.22, 28.88, 68.41, 72.57, 109.66 (d, $J = 3.1$), 114.40, 121.50, 122.03, 122.27 (d, $J = 10.4$), 123.68 (t, $J = 4.9$), 129.89 (d, $J = 3.1$), 132.40, 132.52, 141.93 (dd, $J = 14.6$, $J = 246.20$), 148.80 (dd, $J = 3.1$, $J = 11.5$), 148.99 (dd, $J = 11.5$, $J = 246.2$), 150.68, 163.70, 165.00


^{19}F NMR (376.4 MHz, CDCl_3): -158.6 (1F, dd, $J = 8.0$, $J = 19.5$, Ar-F), -141.61 (1F, dd, $J = 8.0$, $J = 19.5$, Ar-F)

^{29}Si NMR (79.4 MHz, CDCl_3): 2.51 (s, $(\text{CH}_3)_3\text{Si-CH}_2$)

MS M/Z (ESI+): 549.2249 ($\text{C}_{30}\text{H}_{36}\text{F}_2\text{NaO}_4\text{Si}$, M + Na), 527.2402 (100%, $\text{C}_{30}\text{H}_{37}\text{F}_2\text{O}_4\text{Si}$, M + H)

IR: 617, 686, 848, 1010, 1072, 1165, 1249, 1396, 1465, 1604, 1728, 2870, 2954

Assay (HPLC, C18, 235/260 nm, 100% H_3CCN): 99.3%



2',3'-Difluoro-4'-4-((2,4,4-trimethylpentyl)oxy)-[1,1'-biphenyl]-4-yl 4-((2,4,4-trimethylpentyl)oxy)benzoate (21)

Quantities used: Compound **9** (200 mg, 0.5988 mmol), compound **14** (164.7 mg, 0.6588 mmol), EDAC (171.6 mg, 0.898 mmol), DMAP (catalytic), DCM (5 ml). The experimental procedure was as described in the preparation of compound **16**. The title compound was purified by flash chromatography with DCM as the eluent ($R_f = 0.95$) and recrystallised from ethanol, giving the title compound as colourless plates.

Yield: 170 mg (51%)

^1H NMR (400 MHz, CDCl_3): 0.87 (18H, s, 2x $(\text{CH}_3)_3\text{C}$), 0.98 – 1.11 (8H, m, 2x $\text{CH}_3\text{-CH}$ + 2x $(\text{CH}_3)_3\text{C-CHH-CHCH}_3$ -), 1.29 – 1.38 (2H, m, 2x $(\text{CH}_3)_3\text{C-CHH-CHCH}_3$ -), 1.90 – 2.05 (2H, m, 2x $(\text{CH}_3)_3\text{C-CH}_2\text{-CHCH}_3$ -), 3.64 – 3.72 (2H, m, 2x $\text{CH}_3\text{CH-CHHOAr}$), 3.76 – 3.86 (2H, m, 2x $\text{CH}_3\text{CH-CHHOAr}$), 6.71 (1H, ddd, $J = 1.8$, $J = 7.6$, $J = 9.2$, Ar), 6.90 (2H, ddd, $J = 2.1$, $J = 2.8$, $J = 9.2$, Ar), 7.02 (1H, td, $J = 2.4$, $J = 8.5$, Ar) 7.20 (2H, ddd, $J = 2.1$, $J = 2.8$, $J = 8.9$, Ar), 7.47 (2H, dddd, $J = 2.1$, $J = 2.8$, $J = 3.4$, $J = 8.9$, Ar), 8.08 (2H, ddd, $J = 2.1$, $J = 2.8$, $J = 9.2$, Ar)


^{13}C NMR (100.5 MHz, CDCl_3): 21.08, 21.13, 30.72, 30.82, 31.03, 31.06, 32.18, 48.40, 48.49, 75.59, 77.00, 110.65 (d, $J = 2.3$), 115.52, 122.55, 123.13, 123.20 (d, $J = 10.7$), 124.72 (t, $J = 3.8$), 130.99 (d, $J = 3.1$), 133.49, 133.64, 142.95 (dd, $J = 14.6$, $J = 247.0$), 149.22 (dd, $J = 2.3$, $J = 7.7$), 151.29 (dd, $J = 10.7$, $J = 248.6$), 151.71, 164.84, 166.12

^{19}F NMR (376.4 MHz, CDCl_3): -158.55 (1F, dd, $J = 8.0$, $J = 19.5$, Ar-F), -141.71 (1F, dd, $J = 8.0$, $J = 19.5$, Ar-F)

MS M/Z (ESI+): 589.3093 ($\text{C}_{35}\text{H}_{44}\text{F}_2\text{NaO}_4$, M + Na), 567.3263 (100%, $\text{C}_{35}\text{H}_{45}\text{F}_2\text{O}_4$, M + H)

IR: 686, 763, 794, 879, 979, 1072, 1165, 1249, 1465, 1604, 1728, 2870, 2954

Assay (HPLC, C18, 235/260 nm, 100% H_3CCN): 99.2%



2',3'-Difluoro-4'-((3-(trimethylsilyl)propoxy)-[1,1'-biphenyl]-4-yl) 4-((3-(trimethylsilyl)propoxy)benzoate (22)

Quantities used: Compound **10** (150 mg, 0.4464 mmol), compound **15** (252 mg, 1 mmol), EDAC (191 mg, 1 mmol), DMAP (cat), DCM (5 ml). The experimental procedure was as described in the preparation of compound **16**. The title compound was purified by flash chromatography with DCM as the eluent ($R_f = 0.95$) and recrystallised from ethanol, giving the title compound as a white solid.

Yield: 190 mg (75%)

^1H NMR (400 MHz, CDCl_3): 0.00 (18H, s, 2x $(\text{CH}_3)_3\text{Si}$), 0.55 – 0.63 (4H, m, $\text{CH}_2\text{-CH}_2\text{-Si}(\text{CH}_3)_3$), 1.72 – 1.88 (4H, m, 2x $(\text{CH}_3)_3\text{Si-CH}_2\text{-CH}_2\text{-CH}_2\text{O}$), 3.94 – 4.03 (4H, m, 2x CH_2OAr), 6.72 – 6.79 (1H, m, 6.94 (2H, ddd, $J = 1.8$, $J = 2.8$, $J = 8.9$, Ar), 7.06 (1H, td, $J = 2.1$, $J = 8.5$, Ar), 7.23 (2H, ddd, $J = 1.8$, $J = 2.9$, $J = 8.8$, Ar), 7.51 (2H, m, Ar), 8.12 (2H, ddd, $J = 1.8$, $J = 2.8$, $J = 8.8$, Ar),

^{13}C NMR (100.5 MHz, CDCl_3): -1.65, 12.47, 12.64, 23.81, 23.88, 71.03, 72.57, 109.66 (d, $J = 3.1$), 114.40, 121.51, 122.03, 122.25 (d, $J = 10.4$), 123.68 (t, $J = 4.9$), 129.89 (d, $J = 3.1$), 123.42, 132.52, 141.88 (dd, $J = 11.5$, $J = 247.2$), 148.00 (dd, $J = 3.1$, $J = 11.5$), 148.81 (dd, $J = 11.5$, $J = 247.2$), 150.68, 163.65, 165.00


^{19}F NMR (376.4 MHz, CDCl_3): -158.60 (1F, dd, $J = 8.0$, $J = 19.5$, Ar-F), -141.62 (1F, dd, $J = 8.0$, $J = 19.5$, Ar-F)

^{29}Si NMR (79.4 MHz, CDCl_3): 2.47 (s, $(\text{CH}_3)_3\text{Si-CH}_2$), 2.51 (s, $(\text{CH}_3)_3\text{Si-CH}_2$)

MS M/Z (ESI+): 593.2323 ($\text{C}_{31}\text{H}_{40}\text{F}_2\text{NaO}_4\text{Si}_2$, M + Na), 571.2486 (100%, $\text{C}_{31}\text{H}_{41}\text{F}_2\text{O}_4\text{Si}_2$, M + H)

IR: 624, 686, 756, 840, 1002, 1072, 1157, 1195, 1249, 1465, 1604, 1720, 2877, 2947

Assay (HPLC, C18, 235/260 nm, 100% H_3CCN): 98.5%



2',3'-Difluoro-4'-(3-(trimethylsilyl)propoxy)-[1,1'-biphenyl]-4-yl 4-((2,4,4-trimethylpentyl)oxy)benzoate (23)

Quantities used: Compound **10** (150 mg, 0.4464 mmol), compound **14** (250 mg, 1 mmol), EDAC (191 mg, 1 mmol), DMAP (cat), DCM (5 ml). The experimental procedure was as described in the preparation of compound **16**. The title compound was purified by flash chromatography with DCM as the eluent ($R_f = 0.9$) and recrystallised from ethanol, giving the title compound as colourless plates.

Yield: 210 mg (80%)

$^1\text{H NMR}$ (400 MHz, CDCl_3): 0.00 (9H, s, $(\text{CH}_3)_3\text{Si}$), 0.56 – 0.60 (2H, m, $\text{CH}_2\text{-CH}_2\text{-Si}(\text{CH}_3)_3$), 0.91 (9H, s, $(\text{CH}_3)_3\text{-CH}_2$), 1.06 (3H, d, $J = 7.0$, $\text{CH}_2\text{-(CH}_3\text{)CH-CH}_2$), 1.08 (1H, dd, $J = 6.1$, $J = 14.3$, $(\text{CH}_3)_3\text{C-CHH-CHCH}_3$ -), 1.38 (1H, dd, $J = 3.7$, $J = 13.9$, $(\text{CH}_3)_3\text{C-CHH-CHCH}_3$ -), 1.76 (2H, m, $\text{CH}_3\text{-(CH}_2\text{)}_2\text{-CH}_2\text{-CH}_2\text{OAr}$), 1.94 – 2.05 (1H, m, $(\text{CH}_3)_3\text{C-CH}_2\text{-CHCH}_3$ -), 3.71 (1H, dd, $J = 7.3$, $J = 8.8$, $\text{CH}_3\text{CH-CHHOAr}$), 3.83 (1H, dd, $J = 5.4$, $J = 8.8$, $\text{CH}_3\text{CH-CHHOAr}$), 3.99 (2H, t, $J = 7.0$, CH_2OAr), 6.75 (1H, m, , 6.92 (2H, ddd, $J = 1.8$, $J = 2.8$, $J = 8.9$, Ar), 7.06 (1H, td, $J = 2.1$, $J = 8.5$, Ar), 7.23 (2H, ddd, $J = 1.8$, $J = 2.9$, $J = 8.8$, Ar), 7.50 (2H, m, Ar), 8.11 (2H, ddd, $J = 1.8$, $J = 2.8$, $J = 8.8$, Ar)

$^{13}\text{C NMR}$ (100.5 MHz, CDCl_3): 19.97, 29.73, 29.93, 31.07, 47.31, 75.98, 109.62 (d, $J = 3.1$), 115.56, , 122.66 (d, $J = 10.4$), 123.32 (t, $J = 4.9$), 130.17 (d, $J = 3.1$), 141.98 (dd, $J = 10.7$, $J = 247.2$), 147.65 (dd, $J = 3.1$, $J = 11.5$), 148.93 (dd, $J = 10.7$, $J = 247.2$), 155.26, 163.70, 165.00


$^{19}\text{F NMR}$ (376.4 MHz, CDCl_3): -158.58 (1F, dd, $J = 8.0$, $J = 19.5$, Ar-F), -141.60 (1F, dd, $J = 8.0$, $J = 19.5$, Ar-F)

$^{29}\text{Si NMR}$ (79.4 MHz, CDCl_3): 2.50 (s, $(\text{CH}_3)_3\text{Si-CH}_2$)

MS M/Z (ESI+): 591.2725 ($\text{C}_{33}\text{H}_{42}\text{F}_2\text{NaO}_4\text{Si}$, M + Na), 569.2883 (100%, $\text{C}_{33}\text{H}_{42}\text{F}_2\text{O}_4\text{Si}$, M + Na)

IR: 617, 686, 848, 1018, 1072, 1165, 1249, 1465, 1604, 1728, 2870, 2954

Assay (HPLC, C18, 235/260 nm, 100% H_3CCN): 99.4%



2',3'-Difluoro-4'-((2,4,4-trimethylpentyl)oxy)-[1,1'-biphenyl]-4-yl 4-(3-(trimethylsilyl)propoxy)benzoate (24)

Quantities used: Compound **9** (200 mg, 0.5988 mmol), compound **14** (165.9 mg, 0.6586 mmol), EDAC (171.6 mg, 0.898 mmol), DMAP (catalytic), DCM (5 ml). The experimental procedure was as described in the preparation of compound **16**. The title compound was purified by flash chromatography with DCM as the eluent ($R_f = 0.9$) and recrystallised from ethanol, giving the title compound as white plates.

Yield: 310 mg (91%)

$^1\text{H NMR}$ (400 MHz, CDCl_3): 0.00 (9H, s, $(\text{CH}_3)_3\text{Si}$), 0.55 – 0.63 (2H, m, $\text{CH}_2\text{-CH}_2\text{-Si}(\text{CH}_3)_3$), 0.91 (9H, s, $(\text{CH}_3)_3\text{-CH}_2$), 1.07 (3H, d, $J = 6.7$, $\text{CH}_2\text{-}(\text{CH}_3)\text{CH-CH}_2$), 1.09 (1H, dd, $J = 5.8$, $J = 14.0$, $(\text{CH}_3)_3\text{C-CHH-CHCH}_3$ -), 1.37 (1H, dd, $J = 3.7$, $J = 14.0$, $(\text{CH}_3)_3\text{C-CHH-CHCH}_3$ -), 1.72 – 1.84 (2H, m, $\text{CH}_3\text{-(CH}_2)_2\text{-CH}_2\text{-CH}_2\text{OAr}$), 1.95 – 2.08 (1H, m, $(\text{CH}_3)_3\text{C-CH}_2\text{-CHCH}_3$ -), 3.72 (1H, dd, $J = 7.6$, $J = 8.2$, $\text{CH}_3\text{CH-CHHOAr}$), 3.85 (1H, dd, $J = 5.8$, $J = 8.9$, $\text{CH}_3\text{CH-CHHOAr}$), 3.97 (2H, t, $J = 6.7$, CH_2OAr), 6.74 (1H, m,), 6.91 (2H, ddd, $J = 1.8$, $J = 2.8$, $J = 8.9$, Ar), 7.05 (1H, td, $J = 2.1$, $J = 8.5$, Ar), 7.24 (2H, ddd, $J = 1.8$, $J = 2.9$, $J = 8.8$, Ar), 7.51 (2H, m, Ar), 8.13 (2H, ddd, $J = 1.8$, $J = 2.8$, $J = 8.8$, Ar)

$^{13}\text{C NMR}$ (100.5 MHz, CDCl_3): -1.65, 12.64, 19.97, 23.81, 29.74, 29.94, 31.07, 47.31, 71.03, 109.59 (d, $J = 3.4$), 114.40, 121.51, 122.02, 122.61 (d, $J = 10.4$), 123.28 (t, $J = 4.9$), 129.90 (d, $J = 3.1$), 132.42, 132.55, 141.95 (dd, $J = 10.7$, $J = 247.2$), 147.61 (dd, $J = 3.4$, $J = 11.5$), 148.91 (dd, $J = 10.7$, $J = 247.2$), 150.66, 163.65, 165.02


$^{19}\text{F NMR}$ (376.4 MHz, CDCl_3): -158.57 (1F, dd, $J = 19.4$, 6.9, Ar-F), -142.12 (1F, dd, $J = 19.4$, 6.9, Ar-F)

$^{29}\text{Si NMR}$ (79.4 MHz, CDCl_3): 2.46 (s, $(\text{CH}_3)_3\text{Si-CH}_2$)

MS M/Z (ESI+): 591.2730 ($\text{C}_{23}\text{H}_{42}\text{F}_2\text{NaO}_4\text{Si}$, M + Na), 569.2885 (100%, $\text{C}_{33}\text{H}_{43}\text{F}_2\text{O}_4\text{Si}$, M + H)

IR: 509, 617, 756, 794, 1018, 1064, 1165, 1203, 1249, 1404, 1465, 1604, 1728, 2870, 2939

Assay (HPLC, C18, 235/260 nm, 100% H_3CCN): 99.0%



4-(4,4-Dimethylpentyl)oxy-2,3-difluorobromobenzene (26)


Quantities used: 4,4-Dimethylpentanol (2.3 g, 20 mmol), 4-bromo-2,3-difluorophenol (4.2 g, 20 mmol), Triphenylphosphine (5.5 g, 20 mmol), DIAD (4 g, 3.9 ml, 20 mmol), anhydrous THF (40 ml). The experimental procedure was as described in the synthesis of compound 4. The title compound was isolated as a colourless oil *via* flash chromatography with DCM as the eluent ($R_f = 0.95$).

Yield: g (79 %)

$^1\text{H NMR}$ (400 MHz, CDCl_3): 0.76 (9H, s, $(\text{CH}_3)_3\text{C}$), 1.01 – 1.11 (2H, m, $\text{CH}_2\text{-CH}_2\text{-C}(\text{CH}_3)_3$), 1.30 – 1.40 (2H, m, $\text{OCH}_2\text{-CH}_2\text{-CH}_2$), 3.90 (2H, t, $J = 6.7$ Hz, CH_2O), 6.50 – 6.57 (1H, m, Ar), 7.02 – 7.09 (1H, m, Ar)

$^{19}\text{F NMR}$ (376.4 MHz, CDCl_3): -154.66 (1F, ddd, $J = 2.3$ Hz, $J = 6.9$ Hz, $J = 20.7$ Hz, Ar-F), -129.1 (1F, ddd, $J = 2.3$ Hz, $J = 6.9$ Hz, $J = 20.7$ Hz, Ar-F)

MS M/Z (ESI+): 308.0197 [100%, $\text{C}_{13}\text{H}_{17}\text{F}_2\text{OBr}$, M + H]



4'-((4,4-Dimethylpentyl)oxy)-2',3'-difluoro-[1,1'-biphenyl]-4-ol (27)

Quantities used: Compound **26** (2 g, 6.4 mmol), 4-hydroxybenzeneboronic acid (0.969 g, 7.03 mmol, Pd(PPh₃)₄ (50 mg), THF (20 ml), 2M aqueous sodium carbonate (20 ml). The experimental procedure was as described in the preparation of compound **9**. The title compound was purified by flash chromatography with DCM as the eluent (*R_f* = 0.35) and recrystallised from petroleum ether (40-60), giving the title compound a white solid.


Yield: 1.4 g (67%)

¹H NMR (400 MHz, CDCl₃): 0.94 (9H, s, (CH₃)₃C-CH₂), 1.32– 1.37 (2H, m, (CH₃)₃C-CH₂-CH₂), 1.78 – 1.88 (2H, m, CH₂-CH₂-CH₂OAr), 4.05 (2H, t, *J* = 7.0, CH₂OAr), 4.98 (1H, Broad S, Ar-OH), 6.77 (1H, td, *J* = 2.3, *J* = 8.5, Ar), 6.90 (2H, ddd, *J* = 1.8, *J* = 2.8, *J* = 8.5, Ar), 7.05 (1H, ddd, *J* = 2.3, *J* = 8.2, *J* = 8.5, Ar), 7.40 (2H, dddd, *J* = 1.5, *J* = 2.3, *J* = 3.4, *J* = 8.5, Ar)

¹³C NMR (100.5 MHz, CDCl₃): 24.57, 29.28, 30.15, 39.86, 70.74, 109.54 (d, *J* = 2.3), 115.43, 122.61 (d, *J* = 10.7), 123.26 (t, *J* = 3.8), 127.55, 130.06 (d, *J* = 3.1), 141.86 (dd, *J* = 14.6, *J* = 247.0), 147.37 (dd, *J* = 3.1, *J* = 8.4), 148.68 (dd, *J* = 10.7, *J* = 247.8), 155.07

¹⁹F NMR (376.4 MHz, CDCl₃): -158.74 (1F, dd, *J* = 6.9, *J* = 19.5, Ar-F), -141.98 (1F, dd, *J* = 6.9, *J* = 19.5, Ar-F)

MS M/Z (ESI+): 345.0787 (C₁₈H₂₂F₂NaO₂C, M + Na)



2',3'-Difluoro-4'-(pentyloxy)-[1,1'-biphenyl]-4-yl 4-pentylcyclohexane-1-carboxylate (4)

Quantities used: Compound **8** (200 mg, 0.654 mmol), 4-pentylcyclohexanecarboxylic acid (202 mg, 1 mmol), EDAC (191 mg, 1 mmol), DMAP (50 mg), DCM (4 ml). The reaction procedure was as described in the synthesis of compound **16**, the title compound was obtained as colourless needles following recrystallisation from ethanol/THF.

Yield: 224 mg (69%)


^1H NMR (400 MHz, CDCl_3): 0.79 – 0.97 (8H, m), 1.08 – 1.56 (15H, m), 1.71 – 1.85 (4H, m), 2.01 – 2.11 (2H, m, CyH_2), 2.41 (1H, tt, $J = 3.2$ Hz, $J = 12.2$ Hz, CyHCOOAr), 3.98 (2H, t, $J = 7.0$ Hz, ArOCH_2), 6.70 (1H, td, $J = 1.8$ Hz, $J = 8.7$ Hz, ArH), 6.97 (1H, td, $J = 2.3$ Hz, $J = 8.2$ Hz, ArH), 7.05 (2H, ddd, $J = 1.8$ Hz, $J = 2.8$ Hz, $J = 8.7$ Hz, ArH), 7.39 – 7.44 (2H, m, ArH)

^{13}C NMR (100.5 MHz, CDCl_3): 14.09, 14.19, 22.52, 22.78, 26.63, 28.10, 28.93, 29.10, 32.24, 32.36, 37.01, 37.24, 43.74, 69.93, 109.59 (d, $J = 2.3$ Hz), 121.77, 122.21 (d, $J = 10.5$ Hz), 123.63 (t, $J = 3.8$ Hz), 129.81 (d, $J = 2.9$ Hz), 132.45 (m), 141.78 (dd, $J = 15.3$ Hz, $J = 247.3$ Hz), 148.01 (dd, $J = 2.9$ Hz, $J = 8.6$ Hz), 148.95 (dd, $J = 11.5$ Hz, $J = 249.2$ Hz), 150.46, 174.79

^{19}F NMR (376.4 MHz, CDCl_3): -158.64 (1F, ddd, $J = 2.3$ Hz, $J = 8.0$ Hz, $J = 19.5$ Hz, ArF), -141.72 (1F, dd, $J = 8.0$ Hz, $J = 19.5$ Hz, ArF)

MS M/Z (ESI+): 495.3313 [100%, $\text{C}_{29}\text{H}_{38}\text{NaF}_2\text{O}_3$, M + Na], 473.2798 [$\text{C}_{29}\text{H}_{39}\text{F}_2\text{O}_3$, M + H]

Assay (HPLC, 250/275 nm, 100% H_3CCN): 99.9%



2',3'-Difluoro-4'-(4,4-dimethylpentyloxy)-[1,1'-biphenyl]-4-yl 4-hexylcyclohexane-1-carboxylate (30)

Quantities used: Compound **27** (150 mg, 0.469 mmol), 4-pentylcyclohexanecarboxylic acid (150 mg, 0.694 mmol), EDAC (191 mg, 1 mmol), DMAP (50 mg), DCM (5 ml). The reaction procedure was as described in the synthesis of compound **16**, the title compound was obtained as colourless needles following recrystallisation from ethanol.

Yield: 210 mg (86%)


^1H NMR (400 MHz, CDCl_3): 0.87 – 1.06 (14H, m), 1.18 – 1.38 (14H, m), 1.57 (2H, dQuart, $J = 3.4$, $J = 13.1$, (Cy) $\underline{\text{H}}_2$), 1.77 – 1.92 (3H, m, (Cy) $\underline{\text{H}}_2$ + (Cy) $\underline{\text{H}}$), 2.11 – 2.18 (2H, m, (Cy) $\underline{\text{H}}_2$), 2.47 (1H, tt, $J = 3.4$, $J = 12.2$, (Cy) $\underline{\text{H}}$), 4.05 (2H, t, $J = 6.7$, ArOCH_2), 6.76 (1H, ddd, $J = 1.8$, $J = 7.6$, $J = 9.2$, ArH), 7.05 (1H, ddd, $J = 2.1$, $J = 2.4$, $J = 8.9$, ArH), 7.10 (2H, ddd, $J = 2.1$, $J = 2.8$, $J = 8.9$, ArH), 7.49 (2H, dddd, $J = 1.5$, $J = 2.8$, $J = 3.7$, $J = 8.9$, ArH)

^{13}C NMR (100.5 MHz, CDCl_3): 14.22, 22.78, 24.68, 26.99, 29.39, 29.45, 29.99, 31.99, 32.36, 37.01, 37.28, 39.98, 43.74, 70.76, 109.63 (d, $J = 1.9$ Hz), 121.77, 122.24 (d, $J = 11.5$ Hz), 123.64 (t, $J = 3.8$ Hz), 129.81 (d, $J = 2.9$ Hz), 132.44 (m), 141.92 (dd, $J = 15.3$ Hz, $J = 247.3$ Hz), 148.00 (dd, $J = 2.9$ Hz, $J = 8.6$ Hz), 148.94 (dd, $J = 11.5$ Hz, $J = 248.2$ Hz), 150.46, 174.79

^{19}F NMR (376.4 MHz, CDCl_3): -158.51 (1F, ddd, $J = 2.3$, $J = 8.0$, $J = 19.5$, ArF), -141.67 (1F, dd, $J = 8.0$, $J = 19.5$, ArF),

MS M/Z (ESI⁺): 523.2998 [100%, $\text{C}_{31}\text{H}_{42}\text{NaF}_2\text{O}_3$, M + Na], 501.3078 [$\text{C}_{31}\text{H}_{42}\text{F}_2\text{O}_3$, M + H]

Assay (HPLC, 250/275 nm, 100% H_3CCN): 99.7%



2',3'-Difluoro-4'-(3-(trimethylsilyl)propoxy)-[1,1'-biphenyl]-4-yl 4-pentylcyclohexane-1-carboxylate (31)

Quantities used: Compound **10** (200 mg, 0.593 mmol), 4-pentylcyclohexanecarboxylic acid (186 mg, 1 mmol), EDAC (191 mg, 1 mmol), DMAP (50 mg), DCM (10 ml). The reaction procedure was as described in the synthesis of compound **16**, the title compound was obtained as colourless needles following recrystallisation from ethanol.

Yield: 240 mg (78%)

¹H NMR (400 MHz, CDCl₃): 0.00 (9H, s, CH₂-Si-(CH₃)₃), 0.55 – 0.61 (2H, m, CH₂-CH₂-Si(CH₃)₃), 0.86 (3H, t, *J* = 6.7 Hz, CyH-(CH₂)₄-CH₃), 0.96 (2H, dq, *J* = 3.2 Hz, *J* = 16.5 Hz, CyH₂), 1.12– 1.30 (8H, m), 1.48 – 1.58 (2H, dq, *J* = 3.2, *J* = 12.8, CH₂), 1.76 – 1.89 (2H, m, (Cy)CH₂), 1.91 – 2.02 (1H, m, CH₂), 2.06 – 2.15 (2H, m, (Cy)CH₂), 2.46 (1H, tt, *J* = 3.7, *J* = 12.4, CyH), 3.99 (2H, t, *J* = 7.0, ArOCH₂), 6.74 (1H, ddd, *J* = 1.8, *J* = 2.1, *J* = 8.5, ArH), 7.03 (1H, ddd, *J* = 1.5, *J* = 2.1, *J* = 7.3, ArH), 7.10 (2H, ddd, *J* = 2.1, *J* = 2.8, *J* = 8.9, ArH), 7.46 (2H, dddd, *J* = 1.5, *J* = 2.1, *J* = 3.4, *J* = 8.5, ArH)


¹³C NMR (100.5 MHz, CDCl₃): -1.67, 1.11, 12.46, 14.20, 22.77, 26.62, 29.11, 32.24, 32.35, 37.00, 37.23, 43.74, 72.54, 109.62 (d, *J* = 1.9 Hz), 121.77, 122.21 (d, *J* = 10.5 Hz), 123.66 (t, *J* = 4.8 Hz), 129.81 (d, *J* = 2.9 Hz), 132.45 (m), 141.90 (dd, *J* = 15.3 Hz, *J* = 247.3 Hz), 147.93 (dd, *J* = 2.9 Hz, *J* = 10.5 Hz), 148.84 (dd, *J* = 11.5 Hz, *J* = 248.2 Hz), 150.45, 174.80

¹⁹F NMR (376.4 MHz, CDCl₃): -158.64 (1F, ddd, *J* = 2.3, *J* = 8.0, *J* = 19.0, ArF), -141.68 (1F, dd, *J* = 8.0, *J* = 19.0, ArF)

²⁹Si NMR (79.4 MHz, CDCl₃): 2.44 (s, (CH₃)₃Si-CH₂)

MS M/Z (ESI⁺): 539.2942 [100%, C₃₀H₄₂NaF₂O₃Si, M + Na], 516.2921 [C₃₀H₄₂F₂O₃Si, M + H]

Assay (HPLC, 250/275 nm, 100% H₃CCN): 99.6%



2',3'-Difluoro-4'-(2,4,4-trimethylpentyloxy)-[1,1'-biphenyl]-4-yl 4-butylcyclohexane-1-carboxylate (32)

Quantities used: Compound **9** (200 mg, 0.599 mmol), 4-pentylcyclohexanecarboxylic acid (186 mg, 1 mmol), EDAC (191 mg, 1 mmol), DMAP (50 mg), DCM (10 ml). The reaction procedure was as described in the synthesis of compound **16**, the title compound was obtained as colourless needles following recrystallisation from ethanol.

Yield: 212 mg (71%)

^1H NMR (400 MHz, CDCl_3): 0.79 – 1.36 (26H, m), 1.43 – 1.56 (2H, dquart, $J = 3.7$, $J = 14.2$, CH_2), 1.74 – 1.86 (2H, m, (Cy) CH_2), 1.91 – 2.02 (1H, m, CHCH_3), 2.02 – 2.11 (2H, m, (Cy) CH_2), 2.41 (1H, tt, $J = 3.7$, $J = 11.9$, CyH), 3.66 (1H, dd, $J = 7.8$, $J = 9.2$, ArOCHH), 3.80 (1H, dd, $J = 6.0$, $J = 9.2$, ArOCHH), 6.67 (1H, ddd, $J = 1.8$, $J = 2.1$, $J = 8.5$, ArH), 6.98 (1H, ddd, $J = 1.5$, $J = 1.8$, $J = 7.3$, ArH), 7.05 (2H, ddd, $J = 2.1$, $J = 2.8$, $J = 8.9$, ArH), 7.42 (2H, dddd, $J = 1.5$, $J = 1.8$, $J = 3.4$, $J = 8.5$, ArH)

^{13}C NMR (100.5 MHz, CDCl_3): 14.22, 19.97, 22.78, 26.92, 29.11, 29.71, 29.93, 31.07, 32.00, 32.36, 37.01, 37.29, 43.74, 47.31, 75.89, 109.56 (d, $J = 1.8$ Hz), 121.77, 122.15 (d, $J = 10.5$ Hz), 123.59 (t, $J = 4.8$ Hz), 129.80 (d, $J = 2.9$ Hz), 132.48, 141.91 (dd, $J = 14.4$ Hz, $J = 247.3$ Hz), 147.68 (d, $J = 10.5$ Hz), 148.19 (dd, $J = 2.9$ Hz, $J = 7.7$ Hz), 150.14 (d, $J = 11.5$ Hz), 150.45, 174.77

^{19}F NMR (376.4 MHz, CDCl_3): -158.55 (1F, ddd, $J = 2.3$, $J = 8.0$, $J = 19.5$, ArF), -141.76 (1F, dd, $J = 8.04$, $J = 19.5$, ArF).

MS M/Z (ESI+): 537.3313 [100%, $\text{C}_{32}\text{H}_{44}\text{NaF}_2\text{O}_3$, M + Na], 515.3220 [$\text{C}_{32}\text{H}_{45}\text{F}_2\text{O}_3$, M + H]

Assay (HPLC, 250/275 nm, 100% H_3CCN): 99.4%

Supplemental 1D NOE data:




Figure S11: ^1H NMR spectrum of compound **29**, unsaturated.




Figure S12: ^1H 1D NOESY NMR spectrum of compound **29** saturated at 491.20 Hz, 0.98 ppm. The large number of signals results from the saturation of both of the CH_3 environments (0.95 and 0.90 ppm respectively) in the molecule and thus a large number of NOE enhancements result.




Figure S13: ^1H 1D NOESY NMR spectrum of compound **29** saturated at 491.20 Hz, 0.98 ppm. The large number of signals results from the saturation of both of the CH_3 environments (0.95 and 0.90 ppm respectively) in the molecule and thus a large number of NOE enhancements result.




Figure S14: ^1H 1D NOESY NMR spectrum of compound **29** saturated at 722.16 Hz, 1.44 ppm.




Figure S15: ^1H 1D NOESY NMR spectrum of compound **29** saturated at 934.90 Hz, 1.87 ppm.




Figure S16: ^1H 1D NOESY NMR spectrum of compound **29** saturated at 4.08 ppm (2051.92 Hz), this frequency corresponds to the ArOCH_2 environment. The numbered black arrows indicate the assigned NOE enhancements, whereas red arrows indicate unobserved NOE enhancements.




Figure S17: ^1H NMR spectrum of compound **30**, unsaturated.




Figure S18: ^1H 1D NOESY NMR spectrum of compound **30** saturated at 1.34 ppm.




Figure S19: ^1H 1D NOESY NMR spectrum of compound **30** saturated at 0.93 ppm.




Figure SI10: ^1H NMR spectrum of compound **31**, unsaturated.




Figure SI11: ^1H NMR spectrum of compound **31** saturated at 3409.32 Hz, 6.81 ppm




Figure SI12: ^1H NMR spectrum of compound **31** saturated at 2031.41 Hz, 4.06 ppm




Figure SI13: ^1H 1D NOESY NMR spectrum of compound **31** saturated at 323.63 Hz, 0.64 ppm




Figure S114: ^1H 1D NOESY NMR spectrum of compound **31** saturated at 34.59 Hz, 0.07 ppm




Figure S115: ^1H NMR spectrum of compound **32**, unsaturated.




Figure SI16: ^1H 1D NOESY NMR spectrum of compound **32** saturated at 3534.85 Hz, 7.06 ppm.




Figure SI17: ^1H 1D NOESY NMR spectrum of compound **32** saturated at 3404.91 Hz, 6.77 ppm.




Figure SI18: ^1H 1D NOESY NMR spectrum of compound **32** saturated at 1960.10 Hz, 3.88 ppm.




Figure SI19: ^1H 1D NOESY NMR spectrum of compound **32** saturated at 1896.21 Hz, 3.76 ppm.




Figure SI20: ^1H 1D NOESY NMR spectrum of compound **32** saturated at 1048.22 Hz, 2.06 ppm.




Figure SI21: ^1H 1D NOESY NMR spectrum of compound **32** saturated at 730.96 Hz, 1.41 ppm.




Figure S122: ^1H 1D NOESY NMR spectrum of compound **32** saturated at 571.83 Hz, 1.14 ppm.




Figure S123: ^1H 1D NOESY NMR spectrum of compound **32** saturated at 493.82 Hz, 0.955 ppm.

Supplemental DSC data




Figure SI24: DSC trace (10°C min⁻¹) for compound 16.




Figure SI25: DSC trace (10°C min⁻¹) for compound 17.




Figure S126: DSC trace (10°C min⁻¹) for compound 18.




Figure S127: DSC trace (10°C min⁻¹) for compound 19.




Figure S128: DSC trace (10°C min⁻¹) for compound 20.




Figure S129: DSC trace (10°C min⁻¹) for compound 21.




Figure SI30: DSC trace (10°C min⁻¹) for compound 22.




Figure SI31: DSC trace (10°C min⁻¹) for compound 23.




Figure S132: DSC trace (10°C min⁻¹) for compound 24.

Supplementary Information References

- SI1.** H. Kessler, H. Oschkinat, C. Griesinger and W. Bermel, *J. Magn. Reson.*, **1986**, *70*, 106
- SI2.** J. Stonehouse, P. Adell, J. Keeler and A.J. Shaka, *JACS*, **1994**, *116*, 6037
- SI3.** K. Stott, J. Stonehouse, J. Keeler, T.L. Hwang and A.J. Shaka, *JACS*, **1995**, *117*, 4199-4200
- SI4.** Gaussian 09, Revision D.01, M. J. Frisch, G. W. Trucks, H. B. Schlegel, G. E. Scuseria, M. A. Robb, J. R. Cheeseman, G. Scalmani, V. Barone, B. Mennucci, G. A. Petersson, H. Nakatsuji, M. Caricato, X. Li, H. P. Hratchian, A. F. Izmaylov, J. Bloino, G. Zheng, J. L. Sonnenberg, M. Hada, M. Ehara, K. Toyota, R. Fukuda, J. Hasegawa, M. Ishida, T. Nakajima, Y. Honda, O. Kitao, H. Nakai, T. Vreven, J. A. Montgomery, Jr., J. E. Peralta, F. Ogliaro, M. Bearpark, J. J. Heyd, E. Brothers, K. N. Kudin, V. N. Staroverov, R. Kobayashi, J. Normand, K. Raghavachari, A. Rendell, J. C. Burant, S. S. Iyengar, J. Tomasi, M. Cossi, N. Rega, J. M. Millam, M. Klene, J. E. Knox, J. B. Cross, V. Bakken, C. Adamo, J. Jaramillo, R. Gomperts, R. E. Stratmann, O. Yazyev, A. J. Austin, R. Cammi, C. Pomelli, J. W. Ochterski, R. L. Martin, K. Morokuma, V. G. Zakrzewski, G. A. Voth, P. Salvador, J. J. Dannenberg, S. Dapprich, A. D. Daniels, Ö. Farkas, J. B. Foresman, J. V. Ortiz, J. Cioslowski, and D. J. Fox, Gaussian, Inc., Wallingford CT, **2009**.